{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:13:59Z","timestamp":1793909639557,"version":"4.8.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.vaccine.2017.03.049","type":"journal-article","created":{"date-parts":[[2017,3,25]],"date-time":"2017-03-25T14:01:35Z","timestamp":1490450495000},"page":"2308-2314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Chronic hepatitis B: Immunological profile and current therapeutic vaccines in clinical trials"],"prefix":"10.1016","volume":"35","author":[{"given":"Yadira","family":"Lobaina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.03.049_b0005","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.03.049_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0168-8278(03)00378-7","article-title":"EASL international consensus conference on hepatitis B: 13\u201314 september, 2002 Geneva, Switzerland consensus statement (long version)","volume":"39","author":"The EASL Jury","year":"2003","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.vaccine.2017.03.049_b0015","doi-asserted-by":"crossref","first-page":"e1003784","DOI":"10.1371\/journal.ppat.1003784","article-title":"Immune therapeutic strategies in chronic hepatitis b virus infection: virus or inflammation control?","volume":"9","author":"Bertoletti","year":"2013","journal-title":"PLOS Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2017.03.049_b0020","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/cmi.2014.79","article-title":"The immune tolerant phase of chronic HBV infection: new perspectives on an old concept","volume":"12","author":"Bertoletti","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.vaccine.2017.03.049_b0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1756283X08093944","article-title":"Current status of antiviral therapy for hepatitis B","volume":"1","author":"Lau","year":"2008","journal-title":"Therap Adv Gastroenterol"},{"issue":"6","key":"10.1016\/j.vaccine.2017.03.049_b0035","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1038\/ncomms7588","article-title":"Trained immunity in newborn infants of HBV-infected mothers","volume":"25","author":"Hong","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2017.03.049_b0040","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jhep.2014.04.036","article-title":"Occult hepatitis B infection","volume":"61","author":"Pollicino","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0045","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection","volume":"61","author":"Bertoletti","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.vaccine.2017.03.049_b0050","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"10.1016\/j.vaccine.2017.03.049_b0055","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1053\/j.gastro.2011.02.057","article-title":"Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice","volume":"140","author":"Lutgehetmann","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2017.03.049_b0060","doi-asserted-by":"crossref","first-page":"e1002159","DOI":"10.1371\/journal.ppat.1002159","article-title":"Effects of interferon-a\/b on HBV replication determined by viral load","volume":"7","author":"Tian","year":"2011","journal-title":"PLoS Pathog"},{"issue":"8","key":"10.1016\/j.vaccine.2017.03.049_b0065","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of Hepatitis B Virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0070","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nri3169","article-title":"Living in the liver: hepatic infections","volume":"12","author":"Protzer","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-8278(03)00126-0","article-title":"Translation of immunological knowledge into better treatments of chronic Hepatitis B","volume":"39","author":"Bertoletti","year":"2003","journal-title":"J Hepatol"},{"issue":"20","key":"10.1016\/j.vaccine.2017.03.049_b0080","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.3748\/wjg.v18.i20.2443","article-title":"T-cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection","volume":"18","author":"Shimizu","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"17","key":"10.1016\/j.vaccine.2017.03.049_b0085","doi-asserted-by":"crossref","first-page":"8609","DOI":"10.1128\/JVI.76.17.8609-8620.2002","article-title":"Immunogenicity and tolerogenicity of Hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections","volume":"76","author":"Kakimi","year":"2002","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.03.049_b0090","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/hep.20649","article-title":"Regulatory T-cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection","volume":"41","author":"Stoop","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.vaccine.2017.03.049_b0095","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4049\/jimmunol.177.1.739","article-title":"Circulating and liver resident CD4+CD25+ regulatory T-cells actively influence the antiviral immune response and disease progression in patients with hepatitis B","volume":"177","author":"Xu","year":"2006","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2017.03.049_b0100","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1128\/JVI.79.6.3322-3328.2005","article-title":"Modulation of the CD8+-Tcell response by CD4+ CD25+ regulatory T-cells in patients with hepatitis B virus infection","volume":"79","author":"Franzese","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0105","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1016\/j.vaccine.2012.06.063","article-title":"Regulatory T-cells are the most important determinant factor of hepatitis B infection prognosis: a systematic review and meta-analysis","volume":"30","author":"Aalaei-Andabili","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2017.03.049_b0110","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hep.25765","article-title":"Foxp3+ regulatory T-cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice","volume":"56","author":"Stross","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2017.03.049_b0115","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1086\/513296","article-title":"The enigma of concurrent Hepatitis B Surface Antigen (HBsAg) and antibodies to HBsAg","volume":"44","author":"Gerlich","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2017.03.049_b0120","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1440-1746.2004.03529.x","article-title":"Decreased numbers and impaired function of circulating dendritic cell subsets in patients with chronic hepatitis B infection (R2)","volume":"20","author":"Duan","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fimmu.2013.00057","article-title":"NK cells: a double-edged sword in chronic hepatitis B virus infection","volume":"4","author":"Maini","year":"2013","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.03.049_b0130","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.bjid.2015.05.006","article-title":"Natural killer cells in hepatitis B virus infection","volume":"19","author":"Wu","year":"2015","journal-title":"Braz J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2017.03.049_b0135","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T-cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2017.03.049_b0140","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jhep.2010.12.031","article-title":"Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges","volume":"54","author":"Michel","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0145","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2007.09.072","article-title":"Therapeutic vaccination of chronic hepatitis B patients with virus suppression by anti-viral therapy: a randomized, controlled study of co-administration of HBsAg\/AS02 candidate vaccine and lamivudine","volume":"25","author":"Vandepapeliere","year":"2007","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2017.03.049_b0150","doi-asserted-by":"crossref","first-page":"e2565","DOI":"10.1371\/journal.pone.0002565","article-title":"A randomized controlled phase IIb trial of antigenantibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients","volume":"3","author":"Xu","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.049_b0155","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","article-title":"Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings","volume":"59","author":"Xu","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.imlet.2012.11.005","article-title":"Responses to multiple injections with alum alone compared to injections with alum adsorbed to proteins in mice","volume":"149","author":"Wang","year":"2013","journal-title":"Immunol Lett"},{"issue":"3","key":"10.1016\/j.vaccine.2017.03.049_b0165","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J Hepatol"},{"issue":"39","key":"10.1016\/j.vaccine.2017.03.049_b0170","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1016\/j.vaccine.2014.07.027","article-title":"Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study","volume":"32","author":"Gaggar","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.049_b0175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrgastro.2013.13","article-title":"Hepatitis: Long-term therapy of chronic hepatitis B reverses cirrhosis","volume":"10","author":"Lok","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0180","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2017.03.049_b0185","first-page":"302","article-title":"A novel therapeutic HBV vaccine induces potent surface- and core-specific immunogenicity in mice, rhesus macaques and HBV transgenic mice","volume":"46","author":"Marshall","year":"2007","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2017.03.049_b0190","first-page":"S209","article-title":"Treatment of chronic hepatitis B infection with DV-601, a therapeutic vaccine","volume":"54","author":"Spellman","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0195","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1016\/j.vaccine.2013.09.019","article-title":"A hepatitis B vaccine with a novel adjuvant","volume":"31","author":"Plotkin","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.049_b0200","unstructured":"Adis Insight. <http:\/\/adisinsight.springer.com\/drugs\/800022422>; 2014 [accessed 12.07.16]."},{"issue":"S1","key":"10.1016\/j.vaccine.2017.03.049_b0205","first-page":"647A","article-title":"A phase III clinical trial with a therapeutic vaccine containing both HBsAg and HBcAg administered via both mucosal and parenteral routes in patients with chronic hepatitis B","volume":"58","author":"Akbar","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2017.03.049_b0210","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.0818-9641.2004.01278.x","article-title":"Development of a nasal vaccine for chronic hepatitis infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen","volume":"82","author":"Aguilar","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0215","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijid.2006.09.010","article-title":"Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens","volume":"11","author":"Aguilar","year":"2007","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.049_b0220","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s12072-013-9486-4","article-title":"Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B","volume":"7","author":"Al-Mahtab","year":"2013","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.vaccine.2017.03.049_b0225","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/hep.20408","article-title":"Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers","volume":"40","author":"Mancini-Bourgine","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2017.03.049_b0230","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/sj.gt.3302751","article-title":"Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study","volume":"13","author":"Yang","year":"2006","journal-title":"Gene Ther"},{"issue":"3","key":"10.1016\/j.vaccine.2017.03.049_b0235","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/mt.2013.274","article-title":"Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues","volume":"22","author":"Godon","year":"2014","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2017.03.049_b0240","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/gutjnl-2013-305707","article-title":"Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial-ANRS HB02 VAC-ADN","volume":"64","author":"Fontaine","year":"2015","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.vaccine.2017.03.049_b0245","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/cgt.2012.61","article-title":"Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver","volume":"19","author":"Obeng-Adjei","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2017.03.049_b0250","unstructured":"Inovio Pharmaceuticals. <http:\/\/www.inovio.com\/products\/infectious-disease-vaccines\/hepatitis\/hbv\/>; 2015 [accessed 12.07.16]."},{"issue":"2","key":"10.1016\/j.vaccine.2017.03.049_b0255","doi-asserted-by":"crossref","first-page":"e14626","DOI":"10.1371\/journal.pone.0014626","article-title":"Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection","volume":"6","author":"Cavenaugh","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.vaccine.2017.03.049_b0260","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1136\/gutjnl-2014-308041","article-title":"TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T-cells and exerts an antiviral effect in HBV-persistent mice","volume":"64","author":"Martin","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.vaccine.2017.03.049_b0265","unstructured":"Altimmune HepTcell. <http:\/\/www.vaxin.com\/HepTcell.html>; 2015 [accessed 10.08.16]."},{"issue":"2","key":"10.1016\/j.vaccine.2017.03.049_b0270","doi-asserted-by":"crossref","first-page":"e55264","DOI":"10.1371\/journal.pone.0055264","article-title":"The two-component adjuvant IC31H Boosts Type I interferon production of human monocyte-derived dendritic cells via ligation of endosomal TLRs","volume":"8","author":"Szabo","year":"2013","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.vaccine.2017.03.049_b0275","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1136\/gutjnl-2014-308943","article-title":"Towards an HBV cure: state-of-the-art and unresolved questions \u2013 report of the ANRS workshop on HBV cure","volume":"64","author":"Zeisel","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.vaccine.2017.03.049_b0280","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cld.2016.07.001","article-title":"Toward elimination of Hepatitis B virus using novel drugs, approaches, and combined modalities","volume":"20","author":"Boucle","year":"2016","journal-title":"Clin Liver Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2017.03.049_b0285","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/liv.13307","article-title":"Novel targets for hepatitis B virus therapy","volume":"37","author":"Testoni","year":"2017","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.vaccine.2017.03.049_b0290","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4254\/wjh.v7.i9.1272","article-title":"Search for a cure for chronic hepatitis B infection: How close are we?","volume":"7","author":"Phyo","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0295","doi-asserted-by":"crossref","first-page":"32e40","DOI":"10.1016\/j.antiviral.2016.07.004","article-title":"Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection","volume":"133","author":"Vaillant","year":"2016","journal-title":"Antiviral Res"},{"issue":"6","key":"10.1016\/j.vaccine.2017.03.049_b0300","doi-asserted-by":"crossref","first-page":"e0156667","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi Patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.049_b0305","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 Agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.03.049_b0310","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.gastro.2015.11.050","article-title":"Hepatitis B virus-specific and global T-Cell dysfunction in chronic hepatitis B","volume":"150","author":"Park","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.vaccine.2017.03.049_b0315","doi-asserted-by":"crossref","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection","volume":"8","author":"Gardiner","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.049_b0320","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.18_suppl.lba101","article-title":"Phase I\/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. 2015 ASCO Annual Meeting","volume":"33","author":"El-Khoueiry","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0325","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/apt.13751","article-title":"The potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection","volume":"44","author":"Vigano","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"23","key":"10.1016\/j.vaccine.2017.03.049_b0330","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.4254\/wjh.v7.i23.2427","article-title":"Antiviral therapy for chronic hepatitis B: combination of nucleoside analogs and interferon","volume":"7","author":"Hagiwara","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.vaccine.2017.03.049_b0335","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1128\/AAC.00249-15","article-title":"Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.vaccine.2017.03.049_b0340","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: a systematic review","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.vaccine.2017.03.049_b0345","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"214","author":"H\u00f6ner zu Siederdissen","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.049_b0350","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with Adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T12:37:28Z","timestamp":1529930248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17303663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":70,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0264410X17303663"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic hepatitis B: Immunological profile and current therapeutic vaccines in clinical trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}